SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
Sotagliflozin Cuts Heart Failure Risk By Half In High-Risk Patients
This systematic review and network meta-analysis synthesized evidence on three glucose-lowering therapies for patients with coexisting heart…
New drugs for diabetes could also save lives in people with heart failure and lower the need for hospital visits.
Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis
Heart Drug Shows Promise Against Deadly Heart Rhythms
This post hoc analysis of a randomized controlled trial evaluated omecamtiv mecarbil versus placebo in 8232 participants with symptomatic ch…
A heart failure medication already shown to improve pumping strength may also protect against sudden cardiac arrest, especially in patients …
Qiliqiangxin reduces cardiovascular events in heart failure with reduced ejection fraction across LVEF subgroups
Lower heart function gets worse care but this drug helps everyone equally
This post hoc analysis of a Phase 3 RCT in 3110 patients with symptomatic HFrEF found that adding qiliqiangxin to guideline-directed therapy…
This heart drug works for patients with weak hearts just as well as it does for those with slightly stronger pumps
Meta-analysis finds Cimlanod does not reduce mortality in HFrEF, increases hypotension risk
Cimlanod did not reduce death in heart failure patients
This meta-analysis of 459 patients with HFrEF found that Cimlanod did not significantly reduce all-cause or cardiac mortality compared to pl…
A meta-analysis of heart failure patients found Cimlanod did not lower death risk and increased the chance of low blood pressure symptoms.
Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients
Pilot trial shows vericiguat may lower heart failure blood pressure markers
This pilot, randomized, double-blind, placebo-controlled trial enrolled 26 patients with heart failure with reduced ejection fraction (HFrEF…
A small pilot trial found vericiguat reduced a heart failure blood pressure marker, though the study was too small to confirm this benefit.
Higher Lactate Dehydrogenase-to-Albumin Ratio Associated With Increased Readmissions and Mortality in Heart Failure
High Blood Marker Tied to Worse Heart Failure Outcomes
This retrospective cohort study included 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction.
A new blood marker combo can spot heart failure patients most likely to get worse — helping doctors act sooner.
Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts
New research reveals a hidden heart tug-of-war that causes failure
This observational study describes mesoscale contraction patterns in healthy individuals and patients with myocardial infarction.
A hidden tug-of-war inside your heart explains why some pumps fail while others keep going strong during stress.
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction
A Traditional Chinese Capsule Meets Modern Heart Failure Trials
This systematic review and meta-analysis evaluated Qiliqiangxin capsule as adjunctive therapy in 5,580 patients with heart failure with redu…
Adding a traditional Chinese medicine capsule to standard heart failure care reduced deaths and hospital stays in a review of 24 trials.
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…
Research across Heart Failure
Related studies from across the Heart Failure family.
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Aprotinin and tranexamic acid show varying efficacy for hemostasis in neonatal cardiac surgery
Trial Shows Aprotinin May Reduce Blood Loss in Infant Heart Surgery
This network meta-analysis of 27 studies involving 4,556 patients evaluated various hemostatic strategies in neonatal and infant cardiac sur…
A large review of 4,556 patients suggests aprotinin may be more effective than other treatments for managing blood loss during infant heart …
High-intensity interval aerobic exercise improves brachial FMD in coronary artery disease and heart failure
High intensity interval training improves blood flow in heart patients
This network meta-analysis of 6,818 adults with coronary artery disease or chronic heart failure found that high-intensity interval aerobic …
Specific types of intense exercise may improve blood vessel function for people living with heart failure or coronary artery disease.
Research in coronary heart disease shows misalignment between investment and clinical guideline priorities
China's heart disease research focuses on bioequivalence, not innovation
This guideline-based research trend analysis of 3,339 publications identifies a significant gap between current research investments and cli…
A review of 3,339 publications shows China's coronary heart disease research heavily emphasizes bioequivalence studies over innovative drug …
Network meta-analysis reveals resistance training offers largest LVEF gains for adult heart failure patients compared to other exercise types
Resistance training shows greatest heart function boost in network analysis
A network meta-analysis of 3,519 adult heart failure patients found resistance training yielded the greatest improvement in left ventricular…
A network meta-analysis of 3,519 heart failure patients found resistance training improved heart function more than other exercise types, wi…
Conduction system pacing improves LVEF and reduces HF hospitalization vs biventricular pacing in heart failure
Conduction system pacing shows promise for heart failure patients
This systematic review and meta-analysis of 7,019 adult HF patients (LVEF ≤ 50%) found that conduction system pacing (CSP) was associated wi…
A meta-analysis of 7,019 heart failure patients suggests conduction system pacing may improve heart function and reduce hospitalizations com…
Natriuresis-guided diuretic protocols improve fluid removal and shorten hospital stays for acute decompensated heart failure patients compared to standard care approaches in this meta-analysis review
Trial shows natriuresis-guided diuretics help heart failure patients
This systematic review and meta-analysis of 831 patients found that natriuresis-guided diuretic protocols significantly enhanced fluid remov…
A review of 831 patients finds that guiding diuretics by sodium output can increase urine output and shorten hospital stays for acute heart …
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Two-lead CRT-D with atrial sensing shows noninferiority versus three-lead systems in heart failure patients
A simpler heart device works as well as the standard three-wire option for heart failure patients
A randomized trial confirms that a two-lead CRT-D capable of atrial sensing is noninferior to a standard three-lead device. Patients receivi…
A two-wire heart device matched the standard three-wire version in keeping patients alive and avoiding hospital visits over one year.
Renal denervation combined with pulmonary vein isolation increases freedom from atrial fibrillation risk in resistant hypertension patients
Renal denervation may help resistant hypertension patients with heart issues
This systematic review and meta-analysis evaluated renal denervation in patients with resistant hypertension. The pooled analysis included 8…
A meta-analysis suggests renal denervation improves heart and sleep markers in patients with resistant hypertension, though larger trials ar…
TCM and probiotics may offer a promising direction for future precision prevention and management of coronary heart disease
Traditional Chinese medicine and probiotics may help manage coronary heart disease
This narrative review discusses the potential role of traditional Chinese medicine and probiotics in coronary heart disease. The authors not…
A review suggests traditional Chinese medicine and probiotics might offer a new path for managing coronary heart disease, though more proof …
Polygenic scores link to atherosclerosis and ischemic heart disease in Russian populations
Genetic markers help predict heart disease risk for Russian men and women
This meta-analysis review examines genetic predictors of atherosclerosis, ischemic heart disease, and myocardial infarction in a Russian pop…
A large study found specific genes linked to cholesterol levels in Russian people. These genetic scores can help doctors check heart disease…
Questions about Heart Failure with Reduced Ejection Fraction
Does adding qiliqiangxin to my current treatment help my heart failure with reduced ejection fraction?
Yes, adding qiliqiangxin to your current treatment may reduce cardiovascular death and heart failure hospitalization in HFrEF, based on a large trial and meta-analysis.
Full answer →Will taking Cimlanod cause low blood pressure in patients with heart failure with reduced ejection fraction?
Yes, Cimlanod significantly increases the risk of low blood pressure (hypotension) in patients with heart failure with reduced ejection fraction, according to a meta-analysis.
Full answer →Does Cimlanod lower the chance of dying from heart failure with reduced ejection fraction?
No, Cimlanod does not significantly lower the chance of dying from heart failure with reduced ejection fraction based on current evidence.
Full answer →